Lexapro

Escitalopram, the active ingredient in Lexapro, is a selective serotonin reuptake inhibitor (SSRI) presented as an oral tablet for oral use. It is prescribed to treat major depressive disorder and generalized anxiety disorder in adult patients. It is indicated for adult patients who require long‑term management of mood and anxiety symptoms, and it is administered under medical supervision.

GNH USA supplies Lexapro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides batch‑tested product for global distribution.

Lexapro (escitalopram) is used to treat conditions within the depressive and anxiety disorder spectrum.

- Major depressive disorder: alleviates depressive symptoms and improves mood stability. - Generalized anxiety disorder: reduces excessive worry and associated physical tension. - Depressive symptoms in patients with comorbid anxiety: helps stabilize mood when anxiety and depression coexist.

Common side effects are generally mild and transient.

Common Side Effects: - Nausea - Headache - Insomnia - Sexual dysfunction

Serious or Rare Side Effects: - Serotonin syndrome (potentially life‑threatening) - Emergence of suicidal thoughts, especially in young adults - Severe allergic reaction (anaphylaxis)

Before initiating therapy, clinicians should consider several safety factors.

- Assess psychiatric history: monitor for worsening depression or emergence of suicidal thoughts. - Evaluate cardiac risk: avoid in patients with known QT prolongation. - Review concomitant serotonergic drugs: increase risk of serotonin syndrome. - Use caution in hepatic impairment: dose adjustment may be required. - Pregnancy and lactation: discuss risks with prescriber; limited data available. - Store at room temperature: keep in original container, protect from moisture and light.

Escitalopram may interact with other medicines, requiring careful assessment.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs) – risk of severe serotonin syndrome. - Other serotonergic agents (triptans, linezolid, tramadol). - Pimozide or thioridazine – may cause cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (e.g., fluoxetine, omeprazole) – may increase escitalopram levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine) – may reduce efficacy. - NSAIDs or anticoagulants – heightened bleeding risk. - Alcohol – may enhance CNS depression. - Antihistamines – possible additive sedation.